Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

The FDA Approval of First-Line Encorafenib Plus Cetuximab/Chemo in BRAF V600E–Mutant mCRC: With Shubham Pant, MD, MBBS

Shubham Pant, MD, MBBS, a professor in the Department of Gastrointestinal (GI) Medical Oncology and director of clinical research at The University of Texas MD Anderson Cancer Center, discussed lessons learned from the phase 3 BREAKWATER study (NCT04607421), which served as the basis for the FDA’s decision to grant traditional approval to encorafenib (Braftovi) plus cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation, as detected by an FDA-approved test.

Of note, the February 2026 approval builds upon the FDA’s prior decision to grant accelerated approval to encorafenib plus cetuximab and modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) for BRAF V600E–mutant mCRC in December 2024.

Oncology Experts Highlight Ways to Educate and Empower Patients About AE Management

Lipika Goyal, MD; La-Urshalar Brock, FNP, BSN, MSN; Hung Khong, MD; and Colin A. Vale, MD, discussed how they prioritize patient safety in their practices, from educating patients about the treatment-associated adverse effects (AEs) they may experience, to encouraging them to speak up at any time if they develop toxicities or concerning symptoms, in honor of Patient Safety Awareness Week observed from March 8 to 14.

Results of the WISDOM 1.0 Breast Cancer Screening Study: With Laura J. Esserman, MD, MBA

Laura J. Esserman, MD, MBA, the Alfred A. de Lorimier Endowed Chair in General Surgery, a professor Departments of Surgery and Radiology, and affiliate faculty in the Institute for Health Policy Studies at the University of California San Francisco (UCSF), as well as director of the UCSF Breast Care Center and co-leader of the Breast Oncology Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discussed key results from the WISDOM 1.0 breast cancer screening trial (NCT02620852).

Neoadjuvant and Adjuvant EV Plus Pembrolizumab in MIBC: With Matthew D. Galsky, MD

Matthew D. Galsky, MD, the deputy director and director of genitourinary medical oncology; codirector of the Center of Excellence for Bladder Cancer; and a professor of medicine, hematology and medical oncology, and urology, at the Mount Sinai Tisch Cancer Center, discussed efficacy data from the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124), which evaluated enfortumab vedotin-ejfv (EV; Padcev) in combination with pembrolizumab (Keytruda) for the perioperative treatment of patients with muscle-invasive bladder cancer (MIBC) who were eligible for cisplatin-containing therapy and radical cystectomy.

The Role of Cardio-Oncology in Breast Cancer Treatment Decision-Making: With Javid Moslehi, MD

Javid Moslehi, MD, chief of Cardio-Oncology and Immunology at the University of California San Francisco Health, discussed the intersection of cardiovascular health and oncology for the goal of optimizing treatment decision-making and minimizing treatment-related cardiac toxicities for patients with breast cancer.

Moslehi observed that the field of cardio-oncology has experienced significant growth as a direct result of the development of novel treatments for breast cancer and other tumor types, which improve patient prognoses but also frequently introduce complex cardiovascular adverse effects. According to Moslehi, the primary objective of these collaborative discussions between cardiologists and oncologists is to mitigate treatment-related cardiac risks, so patients are not precluded from receiving life-saving therapies.